Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: J Thromb Haemost. 2017 Feb 25;15(4):802–813. doi: 10.1111/jth.13620

Figure 2. SPMs mitigate platelet aggregation.

Figure 2

PRP was generated from healthy human donors and treated with 100 nM SPMs (Lipoxin A4, LXA4; Resolvin D1, RvD1; Resolvin D2, RvD2; 17HDHA; and Maresin 1, Mar1) for 15 minutes prior to initiation of aggregation by 5 μM ADP (A–D). Aggregation was measured for five minutes and the percent change in maximum amplitude was calculated for each SPM relative to vehicle control (0.1% EtOH) (E). Statistical significance was determined by One-way ANOVA with Dunnett’s multiple comparison post-test. *p<0.05, ***p<0.001

HHS Vulnerability Disclosure